[go: up one dir, main page]

TR200102236T2 - Kolesterol-düşürme amilinin kullanımı. - Google Patents

Kolesterol-düşürme amilinin kullanımı.

Info

Publication number
TR200102236T2
TR200102236T2 TR2001/02236T TR200102236T TR200102236T2 TR 200102236 T2 TR200102236 T2 TR 200102236T2 TR 2001/02236 T TR2001/02236 T TR 2001/02236T TR 200102236 T TR200102236 T TR 200102236T TR 200102236 T2 TR200102236 T2 TR 200102236T2
Authority
TR
Turkey
Prior art keywords
cholesterol
lowering agent
dosages
bulus
dihydroxyhept
Prior art date
Application number
TR2001/02236T
Other languages
English (en)
Inventor
Raza Ali
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26315084&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TR200102236(T2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from GBGB9902590.0A external-priority patent/GB9902590D0/en
Priority claimed from GBGB9921062.7A external-priority patent/GB9921062D0/en
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of TR200102236T2 publication Critical patent/TR200102236T2/tr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Cardiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Bulus, (E)-7-[4, (4-flüorofenil)) -6-izopropil-2-[metil (metilsülfonil)amino]pirimidin-5-il]-(3R, 5S)- 3,5-dihidroksihept-6-enoik asidin ya da bunun eczacilik ile ilgili olarak kabul edilebilir bir tuzunun belirli agizdan alinan dozajlarinin ya da dozaj erimlerinin bunun ihtiyaci içinde olan bir hastada faydali bir sekilde lipit seviyelerini ya da lipit oranlarini degistirmek üzere kullanimina oldugu kadar, bu türden dozajlari ihtiva eden agiz yolu ile ilaç olarak verilmeye yönelik olarak adapte edilmis olan sözü edilen bilesigin ya da tuzlarin eczacilik ile ilgili terkiplerine, ve bunlarin hazirlanmasina iliskin metodlara da iliskindir.
TR2001/02236T 1999-02-06 2000-02-01 Kolesterol-düşürme amilinin kullanımı. TR200102236T2 (tr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9902590.0A GB9902590D0 (en) 1999-02-06 1999-02-06 Use of cholesterol-lowering agent
GBGB9921062.7A GB9921062D0 (en) 1999-09-08 1999-09-08 Use of cholestrol-lowering agent

Publications (1)

Publication Number Publication Date
TR200102236T2 true TR200102236T2 (tr) 2001-12-21

Family

ID=26315084

Family Applications (1)

Application Number Title Priority Date Filing Date
TR2001/02236T TR200102236T2 (tr) 1999-02-06 2000-02-01 Kolesterol-düşürme amilinin kullanımı.

Country Status (22)

Country Link
EP (1) EP1150679A1 (tr)
JP (2) JP2002536333A (tr)
KR (1) KR100699287B1 (tr)
CN (1) CN1347320A (tr)
AR (1) AR022462A1 (tr)
AU (1) AU769897B2 (tr)
BR (1) BR0007991A (tr)
CA (1) CA2358641A1 (tr)
CZ (1) CZ20012631A3 (tr)
EE (1) EE04659B1 (tr)
HK (1) HK1040924A1 (tr)
HU (1) HUP0105019A3 (tr)
ID (1) ID30131A (tr)
IL (1) IL144662A0 (tr)
IS (1) IS5996A (tr)
MY (1) MY136382A (tr)
NO (1) NO319827B1 (tr)
NZ (1) NZ512681A (tr)
PL (1) PL349137A1 (tr)
SK (1) SK11112001A3 (tr)
TR (1) TR200102236T2 (tr)
WO (1) WO2000045819A1 (tr)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0001621D0 (en) * 2000-01-26 2000-03-15 Astrazeneca Ab Pharmaceutical compositions
GB0003305D0 (en) 2000-02-15 2000-04-05 Zeneca Ltd Pyrimidine derivatives
SE0103509D0 (sv) * 2001-10-19 2001-10-19 Astrazeneca Ab Rosuvastatin in pre demented states
GB0322552D0 (en) 2003-09-26 2003-10-29 Astrazeneca Uk Ltd Therapeutic treatment
WO2007142581A1 (en) * 2006-06-07 2007-12-13 Astrazeneca Ab Combination product for the treatment or prevention of dyslipidaemia
US8293721B2 (en) 2007-06-20 2012-10-23 Merck Sharpe & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
AU2008266954A1 (en) 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. CETP inhibitors derived from benzoxazole arylamides
CA2689523A1 (en) * 2007-06-20 2008-12-24 Merck Sharp & Dohme Corp. Cetp inhibitors derived from benzoxazole arylamides
EP2216095A1 (en) * 2009-01-27 2010-08-11 Koninklijke Philips Electronics N.V. Microfluidic device for full blood count

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260446A (en) * 1989-12-22 1993-11-09 Basf Aktiengesellschaft Aminothiazoles
JP2648897B2 (ja) * 1991-07-01 1997-09-03 塩野義製薬株式会社 ピリミジン誘導体

Also Published As

Publication number Publication date
AU2305100A (en) 2000-08-25
IS5996A (is) 2001-07-10
CA2358641A1 (en) 2000-08-10
BR0007991A (pt) 2001-11-06
AR022462A1 (es) 2002-09-04
NZ512681A (en) 2003-12-19
IL144662A0 (en) 2002-05-23
HUP0105019A2 (hu) 2002-05-29
NO20013810L (no) 2001-10-03
HUP0105019A3 (en) 2003-02-28
PL349137A1 (en) 2002-07-01
NO319827B1 (no) 2005-09-19
EE04659B1 (et) 2006-08-15
AU769897B2 (en) 2004-02-05
JP2002536333A (ja) 2002-10-29
HK1040924A1 (zh) 2002-06-28
ID30131A (id) 2001-11-08
CZ20012631A3 (cs) 2001-10-17
EP1150679A1 (en) 2001-11-07
KR20010089631A (ko) 2001-10-06
EE200100404A (et) 2002-10-15
MY136382A (en) 2008-09-30
WO2000045819A1 (en) 2000-08-10
NO20013810D0 (no) 2001-08-03
JP2011137023A (ja) 2011-07-14
CN1347320A (zh) 2002-05-01
KR100699287B1 (ko) 2007-03-26
SK11112001A3 (sk) 2002-02-05

Similar Documents

Publication Publication Date Title
RU2407532C9 (ru) Комбинации, предназначенные для лечения заболеваний, включающих пролиферацию клеток
ES2641168T3 (es) Combinaciones que comprenden metotrexato e inhibidores de la DHODH
CR10114A (es) Composiciones farmacéuticas que comprenden inhibidoras de la hmg coa reductasa (divisional del exp. 6687)
DE69812949D1 (de) Hydroxamsäurederivat und antitumormittel enthaltende pharmazeutische zusammensetzung mit verbesserter antitumor-aktivität und/oder verringerten nebenwirkungen
CY1109756T1 (el) Φαρμακευτικες συνθεσεις που περιεχουν κρυσταλλικα αλατα 7-[4-(4-φθοροφαινυλ)-6-ισοπροπυλ-2- [μεθυλ(μεθυλσουλφονυλ)αμινο] πυριμιδιν-5-υλ]-(3r,5s)-3,5-διυδροξυεπτ-6-ενοϊκου οξεος
BR0113331A (pt) Derivados de fenilalanina ou seus sais parmaceuticamente aceitáveis, antagonista de integrina alfa 4, agente terapêutico ou agente preventivo para doenças inflamatórias, e, composição farmacêutica
ATE424810T1 (de) Ein hydrokolloid und einen celluloseether enthaltende tablette mit verzögerter freisetzung
TR200001399T2 (tr) Siklik amin türevleri ve ilaç olarak kullanımları.
TR200103613T2 (tr) Burun içinden tatbik edilen morfini içeren farmasötik formülasyonlar ve yöntemler.
HUP0301380A2 (hu) Roszuvasztatin (ZD-4522) felhasználása heterozigóta örökletes hiperkoleszterolémia kezelésére alkalmas gyógyszerkészítmény előállítására
JP2006508953A5 (tr)
JPH11193282A5 (tr)
ATE359777T1 (de) Fenofibratsäure enthaltende pharmazeutische zusammensetzung und deren physiologisch verträgliche salze und derivate
NO20034863L (no) Deutererte 3-piperidinopropiofenon så vel som legemidler som inneholder disse forbindelser
TR199900336T2 (tr) EAA antagonistleri olarak tetrahidrokinolin türevleri.
BRPI0008228B8 (pt) composição farmacêutica contendo n-benzoil estaurosporina e agentes solubilizantes
TR200103153T2 (tr) Yeni bileşimler
SE0300908D0 (sv) Azaindole derivatives, preparations thereof, uses thereof and compositions containing them
TR200102236T2 (tr) Kolesterol-düşürme amilinin kullanımı.
CA2302568A1 (en) Method, compositions and kits for increasing the oral bioavailability of pharmaceutical agents
IT1314185B1 (it) Composizione farmaceutica per somministrazione di sostanze attivescarsamente solubili in mezzi acquosi
RU2334517C2 (ru) Средство, потенцирующее противоопухолевый эффект, и противоопухолевое средство
ATE13488T1 (de) Gallium-chlorid, ein neues antikrebsmittel.
JP2002536333A5 (tr)
BR0007513A (pt) Fosfatidilinositóis sulfatados, sua preparação euso